Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GENERICS NEWS IN BRIEF
May 19, 2008
- Sugi Pharmacy to Adopt Holding Company System
May 19, 2008
- DSP: Operating Profits Down 12.6% due to Increases in R&D Costs
May 19, 2008
- Women's Healthcare Team to Lead Marketing of Lunabell: Nippon Shinyaku
May 19, 2008
- Will Generics Take Off? (3)
May 19, 2008
- NEW PRODUCT／Sanofi-aventis: Clexane Kit for SC Injection
May 19, 2008
- TOPICS／Mylan Accepted as JPMA Member
May 19, 2008
- Asahi Kasei Pharma: Sales Up 6.5% to \111.2 Bil.
May 19, 2008
- Nihon Chouzai Promotes Dispensing of Generics
May 19, 2008
- Bonalon Drives Teijin's Pharma Business
May 19, 2008
- OBITUARY／Dr Yutaka Mizushima: Former Chairman of LTT-Bio Pharma
May 19, 2008
- Kyowa Hakko: Sales Up 10.7% to \392 Bil.
May 19, 2008
- REGULATORY NEWS IN BRIEF
May 19, 2008
- Santen: Overseas Sales Account for 14.3% of Total Sales
May 19, 2008
- Prof. H. Endo Elected Chairman of Chuikyo
May 19, 2008
- MTPC: Remicade Continues Strong Growth
May 19, 2008
- JMA Has Not Yet Decided on Its Stance Regarding the FPMAJ's Pricing System Reform Proposal: Dr Takeshima
May 19, 2008
- Takeda: Heavy R&D Costs Cut Operating Profits
May 19, 2008
- Korosho to Consider Creating Japanese Version of FDA
May 19, 2008
- Pletaal Launched in Sweden: Otsuka
May 19, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…